At least we have one state that is working in the right direction. I have no idea how to influence this agency to work on neurons. California readers, some help here.
http://blogs.nature.com/news/2012/05/california-stem-cell-agency-shifts-toward-clinical-work.html
I only copied the first 4 paragraphs.
The California Institute of Regenerative Medicine (CIRM) voted on 24 May to accept a new strategic plan which
shrinks or eliminates support for basic research, facilities and
training, while funneling more of its funds toward clinical development.
“The first stage of CIRM was really exploring the field,” said Ellen
Feigal, senior vice president of R&D. “The next five years should be
one of more focus.” By July 2013, the agency hopes to have two
programmes approved for clinical trials in the United States.
During the past five years, nearly half of the approximately $1.3
billion awarded by the agency went toward building new research
facilities and training and career development. Looking ahead, of the
approximately $840 million to be awarded over the next five years,
about three fifths is slotted to go toward development research,
preparing stem cell-based therapeutics for clinical testing, with much
of the rest devoted to translational and basic research. (An additional
$650 million has been approved but not awarded; allocation is roughly an
average between previously awarded funds and future plans.)
No one spoke during a call for comments from the general public, and
the plan was approved by a voice vote with no objections. Board member
Jeff Sheehy voiced concerns about cutting off training and basic
research. CIRM president Alan Trounson and Ellen Feigal said that the
exact allocations could be determined at future meetings. There was
general acknowledgement that difficult funding decisions are ahead. “We
are now in the realm of trade-offs,” said Sheehy.
Also today, CIRM announced $69 million
of grants for translational research. “With these new awards, the agency
now has 52 projects in 33 diseases at varying stages of working toward
clinical trials,” said Jonathan Thomas, governing board chair, said in a
statement.
No comments:
Post a Comment